Showing 3501-3510 of 4062 results for "".
- Luminopia One Demonstrates Safety and Efficacy in Phase 3 Pivotal Trial for Amblyopiahttps://modernod.com/news/luminopia-one-demonstrates-safety-and-efficacy-in-phase-3-pivotal-trial/2480274/Luminopia announced the publication of positive phase 3 pivotal data of its investigational treatment for amblyopia—Luminopia One. Published in Ophthalmology, the study was conducted at 21 academic and community sites in the U.S., in which childre
- Outlook Therapeutics Presents Positive NORSE THREE Safety Data for Lytenava (bevacizumab-vikg)https://modernod.com/news/outlook-therapeutics-presents-positive-norse-three-safety-data-for-lytenava-bevacizumab-vikg-at-euretina/2479575/Outlook Therapeutics announced the presentation of safety data from the NORSE THREE trial evaluating ONS-5010/Lytenava (bevacizumab-vikg) at the EURETINA Virtual 2021 conference on September 12, 2021. The previously announced topline results from the open-label safety study demonstrated that
- Azura Ophthalmics Appoints Steven Altschuler, MD, as Chair of the Boardhttps://modernod.com/news/azura-ophthalmics-appoints-steven-altschuler-md-as-chair-of-the-board/2479486/Azura Ophthalmics announced the appointment of Steven M. Altschuler, MD, as chair of its board of directors. Dr. Altschuler brings more than 20 years of experience building, scaling, and leading health care and biotechnology companies. He currently serves as managing director of Healthcare Ventur
- New Contact Lens Update Focuses on Axial Length Measures in Myopia Managementhttps://modernod.com/news/new-contact-lens-update-focuses-on-axial-length-measures-in-myopia-management/2479488/Issue 61 of
- FDA Advisory Panel Set to Review COVID-19 Booster Doseshttps://modernod.com/news/fda-advisory-panel-set-to-review-covid-19-booster-doses/2479485/The FDA announced that an advisory committee will meet on September 17 to discuss the issue of booster doses of COVID-19 vaccines, according to a FirstWord report. The Vaccines and Related Biological Products Advisory Committee will spec
- Pfizer, BioNTech’s COVID-19 Vaccine on Brink of Full FDA Approvalhttps://modernod.com/news/pfizer-biontechs-covid-19-vaccine-on-brink-of-full-fda-approval/2479464/According to people familiar with the matter, the FDA is expected to grant full approval to Pfizer and BioNTech’s COVID-19 vaccine BNT162b2 as soon as Monday, The New York Times reported. The sources suggested that the agency was aiming to complete the process by August 20, but was still wo
- AAO: Proof of COVID-19 Vaccination Required for All Registrants Attending Annual Meeting in New Orleanshttps://modernod.com/news/aao-proof-of-covid-19-vaccination-required-for-all-registrants-attending-annual-meeting-in-new-orleans/2479461/The American Academy of Ophthalmology’s board of trustees has decided that proof of COVID-19 vaccination will be required for all registrants attending the Academy’s annual meeting in New Orleans. Every AAO 2021 attendee, all Academy staff, exhibitors, and guests will be required to
- Eyeque Announces Series C Closing With More Than $57 Million in Capital Raisedhttps://modernod.com/news/eyeque-announces-series-c-closing-with-more-than-57-million-in-capital-raised/2479459/EyeQue announced that they have closed a Series C round and have raised more than $57 million in capital since the company was founded in 2015. EyeQue aims to bring affordable vision correction with their smartphone vision tests. The company has developed a suite of at-
- Eric D. Donnenfeld, MD, of OCLI Vision Named America’s Best Eye Doctor by Newsweekhttps://modernod.com/news/eric-d-donnenfeld-md-of-ocli-vision-named-americas-best-eye-doctor-by-newsweek/2479447/Eric D. Donnenfeld, MD has been named “America’s Best Eye Doctor 2021” by Newsweek. Dr. Donnenfeld ranks first out of 150 ophthalmologists with a near perfect score for quality of care, continuity of care, and the quality of the technology used in his practice. Dr. Donnenfeld
- Regeneron Terminates Ocular Therapeutix Collaboration to Develop a Sustained-Release Formulation of Aflibercepthttps://modernod.com/news/regeneron-terminates-ocular-therapeutix-collaboration-to-develop-a-sustained-release-formulation-of-aflibercept/2479441/Ocular Therapeutix announced that Regeneron has terminated the option and license agreement collaboration between the companies. The termination became effective August 5, 2021. The collaboration with Regeneron was initially formed in 2016 for the development and commercialization of produ